Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose vs Standard-Dose mBACOD with GM-CSF in AIDS-Related NHL
NCT00000658Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of sargramostim in non-Hodgkin lymphoma (NHL), sponsored by National Institute of Allergy and Infectious Diseases. Status: completed.
02
Drugs
sargramostim
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00000658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000658.